Voy en modo movil y pillado de tiempo para digerir tooooodo esto asi que ahi va el TEMAZO SORPRESA sobre el CONGRESO de hoy, segun leo en Yahoo Board y de ser cierto el asunto, repito, de ser cierto el asunto.
Este es el titulo de la ponencia ( sorpresa?), que va a dar NVAX en unas horas ...
Novavax Breakout Session 2: Vaccines against Viral
2014 guinea ebola virus recombinant glycoprotein (GP) nanoparticle vaccine was highly immunogenic and cross-neutralized 1976 ebola virus GP pseudovirus
G. Smith*1, Y. Liu1, D. Flyer1, L. Fries1, C. Hooper2, G. Glenn1
1Novavax Inc, USA, 2Novavax AB, Sweden, 3Virology Division, USA
Sunday, 26 October 2014: Breakout Session 2: Vaccines against Viral Pathogens - 13:30-15:25
14:10-14:25
-------------
POST DE WILY COYOTE DE YAHOO BOARD SOBRE LA CONFERENCIA
Simple English:
* NVAX used its nanoparticle recombinant tech (same used for RSV)
* Used Matrix-M
* Tested it on animals
* Tested safety
* Tested immunogenicity (i.e. tested blood for generated antibodies)
* Did efficacy test by infecting the animals with a 1976 Ebola pseudovirus to see if the antibodies would actually destroy the virus. The antibodies destroyed the virus.
As our resident expert Lobster told us, only a couple of places in the US (NIH is one) are allowed to have a real Ebola virus (BSL4). Only them can test efficacy for you against a real Ebola virus. The wait-in-line is at least 6 months even in dire emergencies. That's why NVAX had to infect the animals with an Ebola pseudovirus, which is the next best thing. But, the NVAX vaccine itself is developed using the genetic blueprint of an Ebola virus collected recently from Guinea.
An Ebola pseudovirus contains all the surface proteins of Ebola, but with the RNA of a harmless virus. This allows NVAX to test efficacy in many labs across the US (They did it at the "Virology Division" of some University).
Yes, every word I said is deduced from the following lines (100% certainty. No guesswork):
2014 guinea ebola virus recombinant glycoprotein (GP) nanoparticle vaccine was highly immunogenic and cross-neutralized 1976 ebola virus GP pseudovirus
G. Smith*1, Y. Liu1, D. Flyer1, L. Fries1, C. Hooper2, G. Glenn1
1Novavax Inc, USA, 2Novavax AB, Sweden, 3Virology Division, USA